Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 18, 2023Taoiseach Leo Varadkar joins company’s 25-year anniversary celebrations in Clonmel
Taoiseach Leo Varadkar joins company’s 25-year anniversary celebrations in Clonmel CLONMEL, IRELAND (19 May 2023) - Boston Scientific Corporation (NYSE: BSX) will today announce an €80 million...
-
Nov 29, 2022
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass., Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation...
-
Nov 8, 2022Dual-stage algorithm detects and verifies potential heart arrhythmias to help increase clinical efficiency
LONDON, November 8, 2022 – Boston Scientific Corporation (NYSE: BSX) today announced the European launch of the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a long-term diagnostic device...
-
Apr 14, 2022Taoiseach Micheál Martin welcomes new expansion that is expected to enable 300+ jobs in coming years
BOSTON SCIENTIFIC ANNOUNCES €100M INVESTMENT IN GALWAY CAMPUS Taoiseach Micheál Martin welcomes new expansion that is expected to enable 300+ jobs in coming years GALWAY, IRELAND (14 April...
-
Apr 4, 2022More UK patients with Benign Prostatic Enlargement (BPE) should now have improved access to these treatments thanks to inclusion in medtech funding pathway
HEMEL HEMPSTEAD, UK., Mon 4 April, 2022– Boston Scientific Corporation (NYSE: BSX) is pleased to announce the inclusion of two innovative devices in this year’s NHS MedTech Funding Mandate...
-
Feb 15, 2022
MARLBOROUGH, Mass., February 15, 2022– Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced...
-
Dec 8, 2021Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD
Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System...
-
Oct 6, 2021Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement
Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at...
-
Oct 5, 2021Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism
Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular...
-
Oct 5, 2021Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions
Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...
-
Sep 29, 2021Investment earmarked for new technology capabilities and jobs growth
CORK (29 September 2021) – Boston Scientific Corporation (NYSE: BSX) today announced a €30 million investment in its Cork facility to accelerate the development and manufacturing of...
-
Sep 20, 2021EPOCH trial represents the first positive phase 3 study for selective internal radiation therapy
MARLBOROUGH, Mass. (September 20, 2021) – Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment)...
-
Sep 2, 2021Fast-Acting Sub-perception Therapy (FAST) clinically proven to demonstrate significant and sustained pain relief within minutes
MARLBOROUGH, Mass., September 2, 2021 – Boston Scientific (NYSE: BSX) today announced the European launch of FAST Therapy for its WaveWriter Alpha Spinal Cord Stimulator (SCS) Systems. The new...
-
Aug 29, 2021
MARLBOROUGH, Mass., DATE, 2021– Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops...
-
Aug 4, 2021Study is first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for treatment of pulmonary embolism
Boston Scientific Initiates Randomized Controlled Trial for the EkoSonic™ Endovascular System Study is first to compare interventional therapy in combination with anticoagulation to...
-
Jun 24, 2021Acquisition complements company's electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology
Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific...
-
Jun 9, 2021The New Radiopaque Hydrogel Spacer is Visible on CT Scan, an Enhanced Option for Physicians Treating Patients Undergoing Radiation for Prostate Cancer
Boston Scientific Initiates European Launch of Spaceoar Vue™ Hydrogel The New Radiopaque Hydrogel Spacer is Visible on CT Scan, an Enhanced Option for Physicians Treating Patients Undergoing...
-
May 25, 2021Company to begin limited market release in Europe in June
Boston Scientific Completes CE Mark for EXALT™ Model B Single-Use Bronchoscope Company to begin limited market release in Europe in June MARLBOROUGH, Mass., May 25 2021 -- Boston Scientific...
-
May 18, 2021
Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2™ Aortic Valve System MARLBOROUGH, Mass., May 18, 2021 –
-
Feb 26, 2021
LONDON, UK (26 February 2021) The National Institute for Health and Care Excellence (NICE) has issued guidance recommending the use of TheraSphere™ Y-90 Glass Microspheres for the treatment of...
-
Sep 30, 2020SCS portfolio features full-body MRI conditional devices that combine therapy optionsfor personalized pain relief
MARLBOROUGH, Mass., September 30, 2020 – Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems. The...
-
Sep 28, 2020Next-generation Valve Designed to Reduce Paravalvular Leaking, Improve Procedural Efficiency and Treat More Patients with Expanded Indication over Prior Version
Boston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Europe. This next-generation transcatheter aortic valve...
-
Sep 10, 2020
Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Vercise Genus™ Deep Brain Stimulation (DBS) System in...
-
Jan 22, 2020
Paris, France., (22 January, 2020) Boston Scientific Corporation (NYSE: BSX) today announced it has completed CE Mark and initiated a limited market release of the EXALT™ Model D Single-Use...